Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH AntagonistHugh S. Taylor, Kristof Chwalisż, Linda C. Giudice et al.|New England Journal of Medicine|2017Cited by 492
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D’Haens, Marc Ferrante, Tadakazu Hisamatsu et al.|The Lancet|2022Cited by 383
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Geert D’Haens, Remo Panaccione et al.|The Lancet|2022Cited by 312
Long-Term Outcomes of Elagolix in Women With EndometriosisEric S. Surrey, Kristof Chwalisż, Hugh S. Taylor et al.|Obstetrics and Gynecology|2018Cited by 132